...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

DSM Announces June Opening of New cGMP Biopharmaceutical Manufacturing Operation in Brisbane, Australia

| Print |
Monday, 22 April 2013 08:00 (UTC + 2)

DSM Logo

Parsippany, USA, April 22, 2013 / B3C newswire / - DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in June 2013.

DSM Facility Brisbane
Caption:
DSM Biologics Brisbane (center) adjacent to the Translational Research Institute of Queensland
For high resolution, please click on image.

The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products, stated, “We are thrilled to announce the June opening our of new cGMP facility in Brisbane. This operation combines DSM's twenty five years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility. Our partnership with the Government of Queensland and the Commonwealth of Australia has led to this important addition to the Australian biotechnology industry and will be a key contributor to the entire Asia-Pacific region."

Alexander Wessels, President and CEO of DSM Pharmaceutical Products commented, "We are particularly delighted to be bringing our world-class operating ability to the Asia-Pacific region, an important growth area in our strategic development in the biopharmaceutical field; to provide further value to our customers in this region and around the globe." Australia has a vibrant biotechnology industry, but previously had no custom mammalian-based biopharmaceutical manufacturing operation in country. The Queensland Government formed BioPharmaceuticals Australia (BPA), who has partnered with DSM to bring this new facility and operation to Brisbane.

David Hughes, CEO of BioPharmaceuticals Australia said, "The opening of this facility satisfies a national capability gap. Our partnership gives Australia and the wider region access to DSM's extensive experience, expertise and ongoing commitment to developing improved bioprocessing technologies. DSM's operations are a good strategic fit with Australia's existing capabilities and we are already seeing flow-on benefits from local alliances".

The DSM operation will provide cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing. DSM Biologics operates with all standard technologies and also has a portfolio of proprietary technologies for the optimization of biopharmaceutical manufacturing, reducing the cost and risk of mammalian cell culture. The facility has an annual output capability of 500kg and has expansion space available for further capacity utilization.


About DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 23,500 employees deliver annual net sales of around € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmbiologics.com and  www.dsm.com.


Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


For more information:

Guy Tiene
Director, Marketing and Communications
DSM Pharmaceutical Products
tel. +1 973 257 8160; mob. +1 201 650 1667
email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Karen King
President
DSM Biologics
tel. +1 973 257 8427
email This e-mail address is being protected from spambots. You need JavaScript enabled to view it